Antiphospholipid Syndrome: From Pathophysiology to Novel Therapeutic Approaches

Dear Colleagues,

The Special Issue, “Antiphospholipid Syndrome: From Pathophysiology to Novel Therapeutic Approaches”, will focus on the pathophysiological mechanisms, clinical manifestations, and therapeutic approaches of antiphospholipid syndrome.

The antiphospholipid syndrome (APS) is an autoimmune systemic disease characterized by a hypercoagulable state secondary to the presence of antiphospholipid antibodies (aPL), a cluster of autoantibodies directed against plasma proteins that bound membranes phospholipids. In particular, the most frequently found types of aPL are lupus anticoagulant (LA), anticardiolipin antibodies (aCL, IgG and IgM), and anti-β2-glycoprotein I antibodies (anti-β2GPI, IgG, and IgM). APS is clinically associated with vascular thromboses (venous, arterial, or small vessel) and/or pregnancy complications (recurrent embryonic or foetal loss, premature birth).

APS has an estimated prevalence of about 50/100,000 population, and can occur both in patients with underlying autoimmune disease, infections, malignancies, drugs (secondary APS) and in patients without any concomitant clinical condition (primary APS).

This Special Issue is open for both basic and clinical research, or for multidisciplinary and translational approaches, and will also cover original articles as well as reviews on the following topics:

• Antiphospholipid antibodies: pathophysiology and molecular mechanisms;
• Clinical features of antiphospholipid syndrome;
• Traditional and innovative therapeutic approaches for antiphospholipid syndrome.

Dr. Matteo Di Minno
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.